Literature DB >> 10591547

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.

M L Bernal1, B Sinues, I Johansson, R A McLellan, A Wennerholm, M L Dahl, M Ingelman-Sundberg, L Bertilsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10591547

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  16 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

3.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 4.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

5.  Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Authors:  Roland Berecz; Alfredo de la Rubia; Pedro Dorado; Pedro Fernández-Salguero; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-03-28       Impact factor: 2.953

6.  Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.

Authors:  Jorge Vicente; Fabricio González-Andrade; Antonia Soriano; Ana Fanlo; Begoña Martínez-Jarreta; Blanca Sinués
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

7.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

8.  Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?

Authors:  Tom K Birkenhäger; Walter W van den Broek; Peter Moleman; Arnold G Vulto; Jan A Bruijn
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

9.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study.

Authors:  Chiaki Kawanishi; Stefan Lundgren; Hans Agren; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

Review 10.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.